MODIFICATION
A -- Laboratory reagents for molecular biology - Amendment 1
- Notice Date
- 9/17/2019
- Notice Type
- Modification/Amendment
- NAICS
- 424210
— Drugs and Druggists' Sundries Merchant Wholesalers
- Contracting Office
- Department of the Navy, Bureau of Medicine and Surgery, U.S. Naval Medical Research Unit - 6 Peru, Unit 3230 Box 343, American Embassy, DPO AA 34031-0343, Lima, Non-U.S., 34031-0343, Peru
- ZIP Code
- 00000
- Solicitation Number
- VEID190567
- Archive Date
- 10/11/2019
- Point of Contact
- Genaro M Vasquez,
- E-Mail Address
-
genaro.m.vasquez.ln@mail.mil
(genaro.m.vasquez.ln@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- Justification & Approval Other than Full and Open Competition The Virology & Emerging Infections Department of the U.S. Naval Medical and Research Unit No. 6 (NAMRU-6) is seeking to purchase laboratory reagents to be used for molecular diagnosis of influenza virus, adenovirus, Metapneumovirus, Enterovirus, Rhinovirus, Respiratory Syncytial Virus, Mayaro, dengue, Chikungunya, and Zika virus. Specifically, requirement involves reagents for reverse transcription, and real-time platforms used for detection of human influenza viruses (Influenza A-matrix gene and B) and its subtypes (H3, H1pdm/SwH1N1, H1 seasonal and H5) (SOP N6-VIR-MB RV 014); detecting genetic material of Adenovirus in nasal and pharyngeal swab specimens (SOP N6-VIR-MB RV 007); detecting the genetic material of Metapneumovirus (MPV), Enterovirus, Rhinovirus and Respiratory Syncytial Virus in nasal and pharyngeal swabs specimens using a reverse transcription (N6-VIR-MB RV 006); and, amplification of the whole genome of the influenza A virus based on the amplification of full-length gene segments for SNP genotyping, gene expression analysis and genotype (N6-VIR-MB RV 001) and pathogen discovery in respiratory and serum samples collected in our surveillance protocols. All these NAMRU-6 assays have been developed independently for each SOP and involve much time and effort by laboratory technicians, and supervisors for final approval. Reagents used must remain the same as the ones indicated in the SOPs, otherwise the design and validation of these processes would have to be initiated from zero, which would delay all processing and the timely diagnosis of public health relevant pathogens.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/e27ddea20a0dffaf299b43ba0a843fcd)
- Place of Performance
- Address: Venezuela Avenue Block 36 Bellavista-Callao, Lima, Peru
- Record
- SN05447645-W 20190919/190917231029-e27ddea20a0dffaf299b43ba0a843fcd (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |